Evidence map›Paper›PMID 42269052›Full record

ArticleProceedings (Baylor University. Medical Center)2026

Prurigo nodularis en plaque resolved after a loading dose of nemolizumab.

Seo Won Cho, Helen Chen, Aaron Chen, Tarun Sontam, Michelle Tarbox

Abstract readCase Reports
In one paragraph

Article in Proceedings (Baylor University. Medical Center), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Seo Won ChoDepartment of Health Science Center, Texas A&M University Naresh K. Vashisht College of Medicine, Dallas, Texas, USA.ORCID 0009-0001-8244-4574
Helen ChenDepartment of Dermatology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Aaron ChenDepartment of Health Science Center, Texas A&M University Naresh K. Vashisht College of Medicine, Dallas, Texas, USA.
Tarun SontamDepartment of Health Science Center, Texas A&M University Naresh K. Vashisht College of Medicine, Dallas, Texas, USA.
Michelle TarboxDepartment of Dermatology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prurigo nodularis is a chronic pruritic dermatosis often resistant to standard therapies. We report a patient with prurigo nodularis complicated by meralgia paresthetica who achieved complete and durable resolution of pruritus after a single loading dose of nemolizumab, an interleukin-31 receptor A (IL-31RA) antagonist. This case underscores the rapid efficacy of IL-31 blockade and highlights potential neuroimmune interplay in chronic itch disorders.

Indexed as

Antibodies, Monoclonal, HumanizedPrurigoFemaleHumansPruritusAntibodies, Monoclonal, HumanizednemolizumabChronic pruritusIL-13nemolizumabneuroimmune axisprurigo nodularis

Identifiers

PMID42269052
PMCPMC13271330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.